About UrSure
UrSure is a Healthcare company based in Boston (United States) founded in 2015, and was acquired by OraSure in May 2020. Non-invasive urine test for HIV PrEP adherence monitoring is developed. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Viral. Its competitors include Quantalife, Chembio and Senzo; 2 of its 3 listed competitors have raised funding.
Company details
UrSure was founded in 2015 in Boston, United States, within the health diagnostics sector. A non-invasive mass spectrometry-based urine test is provided to assess adherence to HIV preventive medication (PrEP). Two variants of the test are offered, one suited for centralized laboratories and another for decentralized testing environments. This approach allows healthcare providers to prioritize monitoring of high-risk patients based on PrEP usage patterns.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website ursureinc.com
- Acquired by OraSure (May 2020)
- InvestorsOraSure Technologies
& 1 more
- Acquired byOraSure
(May 2020)
Funding Insights of UrSure
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of UrSure with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in UrSure
UrSure has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include OraSure Technologies and MassChallenge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage entrepreneurs are accelerated through MassChallenge's program. | masschallenge.org | Boston, United States | ||
Point-of-care diagnostic devices for oral fluid specimens are provided. | 1987 | orasure.com | Bethlehem, United States |
Investor details for UrSure
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of UrSure
3 dated milestones of UrSure across 5 years, from founding to its latest funding, stage changes and deals.
- Founded UrSure is founded.
- Funding First funding round.
- Exit Acquired by OraSure.
Competitors of UrSure
UrSure has 3 listed competitors in our database, 2 of them funded. They include Quantalife, Chembio and Senzo.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quantalife.com | 2008 | Pleasanton, United States | $28.71M | Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. | ||
| chembio.com | 1986 | Medford, United States | 213 | Proprietary immunoassay platform is utilized for infectious disease diagnostics. | ||
| senzo.com | 2013 | San Francisco, United States | $9.6M | 13 | Point-of-care diagnostic devices for infectious diseases are developed. |
Detailed competitors of UrSure
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as UrSure (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ursure
Complete news archive for UrSure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UrSure
UrSure was founded in 2015 and raised its 1st funding round 2 years after it was founded.
UrSure is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
UrSure was founded in 2015 in Boston, United States, within the health diagnostics sector. A non-invasive mass spectrometry-based urine test is provided to assess adherence to HIV preventive medication (PrEP). Two variants of the test are offered, one suited for centralized laboratories and another for decentralized testing environments. This approach allows healthcare providers to prioritize monitoring of high-risk patients based on PrEP usage patterns.
UrSure's top competitors include Chembio, Quantalife and Senzo.
UrSure has 2 investors. Key investors include OraSure Technologies, and MassChallenge.
Yes. UrSure was acquired by OraSure in May 2020.